Bio-Path Holdings Overview
Bio-Path Holdings (BPTH) has a ROE of 42.64%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow42.64%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bio-Path Holdings (BPTH) currently reports a ROE of 42.64%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Bio-Path Holdings's ROE history and peer comparisons.
Bio-Path Holdings's ROE of 42.64% is higher than the Healthcare sector average of 11.15%. That is roughly 282.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Bio-Path Holdings's current 42.64% should be judged against Healthcare norms (sector average: 11.15%) and against BPTH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 42.64%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Bio-Path Holdings, and consider following BPTH for alerts when major investors trade the stock.
Bio-Path Holdings is classified in the Healthcare sector. On ROE, it currently shows 42.64% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BPTH with unrelated industries.
